Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Position and Intravesical BCG Dwell Time in NMIBC
NCT07474519Phase 4Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Bacillus Calmette Guerin dwell time up to 5 weeks. Started Feb 2026; status: recruiting.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07474519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07474519.